Syncor to distribute diagnostic radiopharmaceutical:
This article was originally published in Clinica
Executive Summary
Syncor International will exclusively distribute Massachusetts General Hospital's F-18 Fluorodeoxyglucose (FDG), a diagnostic pharmaceutical for use in Positron Emission Tomography (PET). The Woodland Hill, California-based company will be responsible for actively marketing the product to increase usage of FDG, which is used in oncology, cardiology and neurology. The hospital has its own commercial nuclear pharmacy dedicated to FDG and a research budget of more than $200 million a year.